Analysts Conflicted on These Healthcare Names: Incyte (INCY) and Masimo (MASI)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY) and Masimo (MASI).
Oppenheimer analyst Jay Olson assigned a Buy rating to Incyte today and set a price target of $110.00. The company’s shares closed last Monday at $79.87, close to its 52-week low of $75.52.
According to TipRanks.com, Olson is a 3-star analyst with an average return of 3.1% and a 45.4% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and Enanta Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Incyte with a $92.00 average price target.
See today’s analyst top recommended stocks >>
In a report released today, Michael Matson from Needham assigned a Hold rating to Masimo. The company’s shares closed last Monday at $234.71.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 17.0% and a 72.2% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
Masimo has an analyst consensus of Moderate Buy, with a price target consensus of $297.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.